BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beard TL, Michalsky C, Candiotti KA, Rider P, Wase L, Habib AS, Demitrack MA, Fossler MJ, Viscusi ER. Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. Pain Ther 2021;10:401-13. [PMID: 33210266 DOI: 10.1007/s40122-020-00216-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Lim SY, Cengiz P. Opioid tolerance and opioid-induced hyperalgesia: Is TrkB modulation a potential pharmacological solution? Neuropharmacology 2022;220:109260. [PMID: 36165856 DOI: 10.1016/j.neuropharm.2022.109260] [Reference Citation Analysis]
2 Vidal-torres A, Fernández-pastor B, García M, Ayet E, Cabot A, Burgueño J, Monroy X, Aubel B, Codony X, Romero L, Pascual R, Serafini MT, Encina G, Almansa C, Zamanillo D, Merlos M, Vela JM. Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.09.018] [Reference Citation Analysis]
3 Viscusi ER. A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain. Expert Rev Neurother 2022. [PMID: 35502668 DOI: 10.1080/14737175.2022.2072731] [Reference Citation Analysis]
4 Varrassi G. Pain and Therapy in the Realm of a Storm. Pain Ther 2022. [PMID: 35149983 DOI: 10.1007/s40122-022-00360-6] [Reference Citation Analysis]
5 Simpson KN, Fossler MJ, Wase L, Demitrack MA, Wandstrat TL. Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events. Expert Rev Pharmacoecon Outcomes Res 2022. [PMID: 35129031 DOI: 10.1080/14737167.2022.2038137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Azzam AAH, Lambert DG. Preclinical Discovery and Development of oliceridine (Olinvyk®) for the Treatment of Post-Operative Pain. Expert Opin Drug Discov 2021. [PMID: 34817313 DOI: 10.1080/17460441.2022.2008903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Noble F, Marie N. Biased Opioid Ligands: Revolution or Evolution? Front Pain Res 2021;2. [DOI: 10.3389/fpain.2021.722820] [Reference Citation Analysis]
8 Vearrier D, Grundmann O. Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids. J Clin Pharmacol 2021;61 Suppl 2:S70-88. [PMID: 34396552 DOI: 10.1002/jcph.1923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hammer GB, Khanna AK, Michalsky C, Wase L, Demitrack MA, Little R, Fossler MJ, Ayad S. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. Pain Ther 2021. [PMID: 34351590 DOI: 10.1007/s40122-021-00299-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Tan HS, Habib AS. Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence. J Pain Res 2021;14:969-79. [PMID: 33889018 DOI: 10.2147/JPR.S278279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
11 Liu Y, Hu Q, Yang J. Oliceridine for the Management of Acute Postoperative Pain. Ann Pharmacother 2021;55:1283-9. [PMID: 33423508 DOI: 10.1177/1060028020987679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]